XBP1 and colitis: Inhibition of miR-330-3p showed a significant upregulation of XBP1 expression and reduction of weight loss and DAI elevation in DSS-induced colitis, which is consistent with the previous finding that activation of XBP1 inhibited the pathogenesis of ulcerative colitis [11].